Zacks Investment Research·Jun 26, 2026
Why the Market Dipped But DaVita HealthCare (DVA) Gained TodayIn the most recent trading session, DaVita HealthCare (DVA) closed at $217.04, indicating a +1.72% shift from the previous trading day.
DaVita Inc.(DVA)Earnings, Financials & Key Ratios
DVA•NYSE
$235.71
24.8× P/E·Price updated Jul 6, 2026
AboutDaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.Show more
- Revenue$13.64B+6.5%
- EBITDA$2.73B-3.1%
- Net Income$747M-20.2%
- EPS (Diluted)9.51-11.4%
- Gross Margin27%-17.9%
- EBITDA Margin19.98%-9.0%
- Operating Margin14.74%-9.7%
- Net Margin5.47%-25.1%
- ROE45.96%+18.7%
DVA Price & Volume
DaVita Inc. (DVA) stock price & volume — 10-year historical chart
Loading chart...
Aggressive Capital Allocation Strains Equity Solvency Profile
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Stable
Profitability:Moderate
Financial:Vulnerable
Cash Flow:Mixed
Primary Risk:Excessive leverage and reimbursement
Key Thesis Takeaways
- DaVita maintains a stable revenue growth profile, evidenced by consistent quarterly year-over-year increases between 4.6% and 9.9%, yet the firm faces significant long-term risks from its aggressive capital return strategy.
- The systematic erosion of equity to a negative $755.5 million by 2026Q1, coupled with a debt-to-equity ratio that has surged to 12.61, suggests a precarious financial structure that may limit future operational flexibility.
- Investors should monitor the company's ability to manage its $13.2 billion debt load while navigating ongoing reimbursement volatility and margin pressure in the dialysis sector.
Verdict Logic
while the company maintains a dominant market position, the combination of a 12.61 debt-to-equity ratio and negative equity suggests that the current valuation of 22.82x P/E may not fully account for the underlying balance sheet risks.
DVA Growth Metrics
DaVita Inc. (DVA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-0.1%
5 Years3.39%
3 Years5.53%
TTM6.68%
Profit CAGR
10 Years10.72%
5 Years-0.7%
3 Years10.04%
TTM-9.1%
EPS CAGR
10 Years22.5%
5 Years8.28%
3 Years18.54%
TTM-1.49%
Return on Capital
10 Years11.83%
5 Years12.28%
3 Years13.3%
Last Year14.04%
DVA Recent Earnings
DaVita Inc. (DVA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$2.87+19.1%
$2.41
Rev
$3.4B+1.8%
$3.4B
Q1 2026
Feb 2, 2026Metric
Actual
Est
EPS
$3.40+4.9%
$3.24
Rev
$3.6B+3.2%
$3.5B
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$2.51-20.8%
$3.17
Rev
$3.4B-0.2%
$3.4B
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$2.95+9.3%
$2.70
Rev
$3.4B-1.8%
$3.4B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $2.87vs $2.41+19.1% | $3.4Bvs $3.4B+1.8% |
| Q1 2026 | Feb 2, 2026 | $3.40vs $3.24+4.9% | $3.6Bvs $3.5B+3.2% |
| Q4 2025 | Oct 29, 2025 | $2.51vs $3.17-20.8% | $3.4Bvs $3.4B-0.2% |
| Q3 2025 | Aug 5, 2025 | $2.95vs $2.70+9.3% | $3.4Bvs $3.4B-1.8% |
Based on last 12 quarters of dataView full earnings history →
Latest DVA News
Recent stock market news and headlines for DaVita Inc. (DVA)
Investors Business Daily·Jun 26, 2026
If You Own These 10 Stocks — Analysts Think You Should Sell ThemAnalysts don't like to put "sell" ratings on S&P 500 stocks. So the fact they're willing to do it with some is worth your attention.
Zacks Investment Research·Jun 26, 2026
Best Growth Stocks to Buy for June 26thLYB, HRB and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 26th, 2026.
Zacks Investment Research·Jun 24, 2026
DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to NoteThe latest trading day saw DaVita HealthCare (DVA) settling at $213.04, representing a +1% change from its previous close.
Zacks Investment Research·Jun 24, 2026
DaVita Stock Benefits From Expanding Community-Based Kidney CareDVA is expanding kidney care through outpatient, home-centered and value-based programs while investing in AI-enabled scheduling.
Peers Comparison
Key metrics vs top competitors for DaVita Inc. (DVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $235.71 | $15.13B | 24.79 | 6.46% | 5.47% | 45.96% | — | |
| $23.61 | $13B | 12.31 | 1.51% | 4.89% | 6.68% | — | |
| $29.64 | $267.97M | 15.12 | 27.11% | 18.05% | 11.51% | — | |
| $417.99 | $379.6B | 31.59 | 11.81% | 2.68% | 11.54% | — | |
| $392.86 | $47.17B | 39.92 | 10.06% | 0.82% | 6.17% | — | |
| $66.05 | $32.62B | -4.85 | 19.44% | -3.25% | -28.6% | — |
Compare DVA vs Peers
DaVita Inc. (DVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DVA SEC Filings & Documents
DaVita Inc. (DVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 2, 2026·SEC
Material company update
Nov 25, 2025·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when DVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DVA Frequently Asked Questions
DaVita Inc. (DVA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is DaVita Inc.'s revenue?
DaVita Inc. (DVA) reported $13.84B in revenue for fiscal year 2025. This represents a 4970% increase from $272.9M in 1996.
How fast is DaVita Inc. growing?
DaVita Inc. (DVA) grew revenue by 6.5% over the past year. This is steady growth.
Is DVA profitable?
Yes, DaVita Inc. (DVA) is profitable, generating $781.4M in net income for fiscal year 2025 (5.5% net margin).
Dividend & Returns
What is DVA's return on equity?
DaVita Inc. (DVA) has a return on equity (ROE) of 46.0%. This is excellent, indicating efficient use of shareholder capital.
What is DaVita Inc.'s free cash flow?
DaVita Inc. (DVA) generated $1.49B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.